PRGO - Perrigo Company plc

NYSE - NYSE Delayed Price. Currency in USD
72.27
-0.16 (-0.22%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close72.43
Open72.72
Bid0.00 x 800
Ask0.00 x 800
Day's Range72.07 - 73.11
52 Week Range67.53 - 95.93
Volume768,298
Avg. Volume1,429,259
Market Cap9.889B
Beta0.92
PE Ratio (TTM)43.25
EPS (TTM)1.67
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & Yield0.76 (1.03%)
Ex-Dividend Date2018-08-30
1y Target Est81.23
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    Haeggquist & Eck, LLP is Investigating Claims Against Perrigo’s Directors and Officers for Breach of Fiduciary Duty Concerning Revenue Recognition for MS Pharmaceutical Tysabri

    Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether directors and officers of Perrigo Company plc (“Perrigo”) (PRGO) breached their fiduciary duties to Perrigo and its shareholders. If you are a Perrigo shareholder, you are encouraged to contact Amber Eck at Haeggquist & Eck for additional information. Perrigo, together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide.

  • Investors Are Undervaluing Perrigo Company plc (NYSE:PRGO) By 28.77%
    Simply Wall St.9 days ago

    Investors Are Undervaluing Perrigo Company plc (NYSE:PRGO) By 28.77%

    Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Perrigo Company plc (NYSE:PRGO) as an investment opportunity by projecting itsRead More...

  • Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod
    Zacks16 days ago

    Perrigo's OTC Version of Diarrhea Drug Imodium Gets FDA Nod

    Perrigo (PRGO) announces approval of over-the-counter equivalent of Imodium Multi-Symptom Relief tablet in the United States.

  • Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Imodium® Multi-Symptom Relief
    PR Newswire19 days ago

    Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Imodium® Multi-Symptom Relief

    TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium® Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg). This product will be packaged and marketed as store brands or retailer 'own label' brands and will provide consumers with a high-quality, value alternative to the national brand. Perrigo is finalizing plans to launch its wholly owned store brand loperamide hydrochloride and simethicone tablets, 2 mg/125 mg, in the fourth quarter of 2018.

  • Perrigo to Reschedule Investor Event
    PR Newswire27 days ago

    Perrigo to Reschedule Investor Event

    TASE: PRGO) today announced that it has postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25, 2018. The Company will provide an update on timing at a later date for an in-person investor meeting to communicate these important strategies and initiatives to drive long-term growth. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of PRGO earnings conference call or presentation 9-Aug-18 12:30pm GMT

    Q2 2018 Perrigo Company PLC Earnings Call

  • Perrigo Company plc (NYSE:PRGO): Can It Deliver A Superior ROE To The Industry?
    Simply Wall St.last month

    Perrigo Company plc (NYSE:PRGO): Can It Deliver A Superior ROE To The Industry?

    This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Mallinckrodt and Perrigo Company

    The Dow Jones Industrial Average jumped 0.35 percent to close at 25,758.69, while the S&P 500 Index have gained 0.24 percent to close at 2,857.05. The Nasdaq Composite Index increased 0.06 percent to close at 7,821.01.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Perrigo Company

    NEW YORK, NY / ACCESSWIRE / August 20, 2018 / U.S. equities continued to rally in Friday as hopes of easing trade tensions between the U.S. and China outweighed recent concerns of the currency crisis in ...

  • Benzinga2 months ago

    Perrigo Needs 'Meet-Or-Beat' Quarters, Deutsche Bank Says In Downgrade

    Perrigo Company PLC, (NYSE: PRGO ) was hit with a downgrade from Deutsche Bank after an eventful week that included the announced separation of its prescription pharmaceutical business and its second-quarter ...

  • The Wall Street Journal2 months ago

    [$$] Perrigo to Separate Its Prescription Pharmaceutical Business

    Perrigo Co. plans to shed its prescription pharmaceutical unit, which accounts for about one-fifth of total revenue, following a strategic review of its portfolio. Perrigo, which makes private-label products such as cold medicines and infant formula, said Thursday its board believes the separation would create shareholder value and allow the company to focus on expanding its consumer business. Perrigo said it plans to complete the separation in the second half of 2019.

  • Moody's2 months ago

    Perrigo Company plc -- Moody's says Perrigo's ratings unaffected following announced separation of prescription business

    Moody's Investors Service ("Moody's") commented that Perrigo Company plc's ("Perrigo") Baa3 senior unsecured rating and stable outlook are not immediately impacted by its announcement on August 9, 2017, that the company plans to separate its Prescription Pharmaceutical business ("Rx business"). For additional information please refer to Moody's Issuer Comment on Perrigo Company plc available on www.moodys.com.

  • Barrons.com2 months ago

    Mylan, Perrigo Earnings: Look Out Below!

    Shares of Mylan (MYL) and Perrigo (PRGO) are falling on Thursday after the drugmakers revised their full-year outlooks lower. Where we were: While health-care and pharmaceutical stocks have outperformed the broader market, both Perrigo and Mylan have been left out of the party, falling 19.1% and 12.7%, respectively, year to date. The second-quarter earnings season has been quite strong, but it's been a tough couple of days for specialty pharmaceutical companies.

  • Perrigo plans to separate prescription pharma business
    Reuters2 months ago

    Perrigo plans to separate prescription pharma business

    Generic drugmakers such as Perrigo, Mylan (MYL.O) and Teva Pharmaceutical Industries (TEVA.TA) have suffered over the past few years as price erosion has pressured their bottom lines. "The company (Perrigo) has been actively discussing this potential separation for some time and the lack of a buyer thus far to us suggests this won't be easy," RBC Capital Markets analyst Randall Stanicky said. Perrigo's announcement comes just a day after larger rival Mylan said it was evaluating all strategic options, citing a tough U.S. environment for generic drugmakers.

  • Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down
    Zacks2 months ago

    Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down

    Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.

  • MarketWatch2 months ago

    Perrigo stock drops 6.5% after Q2 revenue miss, guidance cuts; company plans to separate drug unit

    Perrigo Co. PLC (PRGO) shares dropped 6.5% in Thursday premarket trade after the Ireland-based generic drugmaker reported a second-quarter revenue miss and made cuts to its 2018 guidance. Perrigo said weakness in its prescription drug business drove the results, and separately announced plans to parcel out the unit -- which sells various topical generic products -- from its consumer business. The company is considering options like a business separation, sale or merger, which would likely take place in the second half of next year.

  • CNBC2 months ago

    Stocks making the biggest moves premarket: VIAB, TRCO, BKNG, PRTY & more

    Check out the companies making headlines before the bell: Viacom VIAB – The media company reported adjusted quarterly profit of $1.18 per share , 11 cents a share above estimates. Revenue was essentially in line with forecasts, but was down about 3.

  • Perrigo (PRGO) Beats Q2 Earnings Estimates
    Zacks2 months ago

    Perrigo (PRGO) Beats Q2 Earnings Estimates

    Perrigo (PRGO) delivered earnings and revenue surprises of 0.83% and -3.48%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE2 months ago

    Perrigo Co. Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Perrigo Co. Plc (NYSE: PRGO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...

  • Associated Press2 months ago

    Perrigo: 2Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had profit of 26 cents. Earnings, adjusted for one-time gains and costs, came to $1.22 per share. The results surpassed Wall Street expectations. ...

  • Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
    PR Newswire2 months ago

    Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

    TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, over-the-counter ("OTC") Nasonex® (mometasone furoate monohydrate) Nasal Spray. Under the terms of the agreement, Perrigo holds exclusive rights to market, sell, and distribute a non-prescription version of Nasonex® OTC in the United States following Perrigo's receipt of all necessary regulatory approvals.